VCM
NGNE icon

Versant Capital Management’s Neurogene NGNE Stock Holding History

Versant Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33
Closed -$680 – 2827
2025
Q4 		$680 Hold
33
– – ﹤0.01% 2564
2025
Q3 		$572 Hold
33
– – ﹤0.01% 2559
2025
Q2 		$493 Buy
+33
New +$518 ﹤0.01% 2553

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Versant Capital Management's NGNE Position: Q1 2026 in Review

Versant Capital Management sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 33 shares — an estimated $680 sold.

Versant Capital Management first reported a position in NGNE in Q2 2025 and held it in 3 quarters. The position peaked at $680 in Q4 2025. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Versant Capital Management reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • Versant Capital Management sold 33 Neurogene shares in Q1 2026, an estimated $680.
  • Versant Capital Management first reported a position in Neurogene in Q2 2025 and held it in 3 quarters.
  • Versant Capital Management's Neurogene position peaked at $680 in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Versant Capital Management's 13F filing for Q1 2026, filed 7 Apr 2026.